Clinical Benefits of Seroquel XR in Anxiety Disorder
Status:
Unknown status
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This research will explore whether Quetiapine XR used primarily to treat psychosis may also
cover for comorbid anxiety disorder and offer advantages in patients with schizophrenia and
comorboid anxiety disorder. Preliminary data on pharmacological properties of Quetiapine and
its metabolites and intuitive impression from our clinical experience lead to believe that
Seroquel XR use in monotherapy may offer advantages over other antipsychotics in treating
co-morbid anxiety disorder in patients suffering from schizophrenia. This open label switch
study conducted in a schizophrenic population intends to verify this hypothesis.
Phase:
Phase 3
Details
Lead Sponsor:
Corporation de Recherche en Neuropsycho Pharmacologie de Quebec